CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study

Oligodeoxynucleotides containing immunostimulatory CpG motifs (CpG ODN) act as potent Th1-like immune enhancers with many antigens in animal models. We have extended these observations to the first clinical evaluation of the safety, tolerability and immunogenicity of CPG 7909 when added to a commerc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical immunology 2004-11, Vol.24 (6), p.693-701
Hauptverfasser:	Cooper, C L, Davis, H L, Morris, M L, Efler, S M, Adhami, M Al, Krieg, A M, Cameron, D W, Heathcote, J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Immunologic - administration & dosage Adjuvants, Immunologic - toxicity Adolescent Adult Antibody Formation Double-Blind Method Female Hepatitis B Surface Antigens - administration & dosage Hepatitis B Surface Antigens - immunology Hepatitis B Vaccines - administration & dosage Hepatitis B Vaccines - toxicity Humans Immunophenotyping Male Membrane Glycoproteins - agonists Oligodeoxyribonucleotides - administration & dosage Oligodeoxyribonucleotides - toxicity Receptors, Cell Surface - agonists T-Lymphocytes - immunology T-Lymphocytes, Cytotoxic - immunology Toll-Like Receptor 9 Toll-Like Receptors Vaccines, Synthetic - administration & dosage Vaccines, Synthetic - toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!